RRML - Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17


Advanced search


Top 10 downloaded articles
- December 2022 -
 
Downregulation of hsa-miR-4328... 5
Normality assessment, few para... 4
Setting up an own laboratory p... 3
The relationship between matri... 2
New Para-Clinical Investigatio... 2
New high-throughput liquid chr... 2
General Principles of Haematop... 2
Genetic risk factors for throm... 2
The importance of the new prog... 2
Detection of chromosomal imbal... 2

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 28(2)/2020 DOI:10.2478/rrlm-2020-0007
XML
TXT

Review

Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia

Letitia Elena Radu, Roxana Corina Sfetea, Constantin Virgiliu Arion, Anca Colita

Correspondence should be addressed to: Letitia Elena Radu

Abstract:

cardiac impairment during the treatment of pediatric patients is extremely important, both for modulating future chemotherapy and for administering cardioprotective agents. Long term monitoring after chemotherapy helps to identify the risk of late cardiotoxicity among cancer survivors. There are several biomarkers, already in use or still under study, which may represent an operator-independent alternative for echocardiography in the diagnosis of cardiotoxicity. In case of cardiac damage, the clinician has options for treating or limiting the progression, either with the use of already approved agents, such as Dexrazoxane, or by administrating other cardioprotective drugs. International experts are still attempting to establish the best algorithm for early detection of cardiotoxicity, as well as the most efficient treatment plan in case of already existing myocardial damage in these patients. We present a review on treatment-related cardiotoxicity, including mechanisms of development, useful biomarkers and treatment options, after carefully analyzing specialty literature.

Keywords: acute lymphoblastic leukemia, cardiotoxicity, biomarkers, cardioprotective agents

Received: 11.10.2019
Accepted: 31.12.2019
Published: 5.2.2020

 
  PDF Download full text PDF
(438 KB)
     
 
How to cite
Radu LE, Sfetea RC, Arion CV, Colita A. Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia. Rev Romana Med Lab. 2020;28(2):133-44. DOI:10.2478/rrlm-2020-0007